Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis
BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fundação Oswaldo Cruz (FIOCRUZ)
2020-07-01
|
| Series: | Memorias do Instituto Oswaldo Cruz |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762020000100328&tlng=en |
| _version_ | 1797756861753065472 |
|---|---|
| author | María José Germanó Esteban Sebastián Lozano María Victoria Sanchez Flavia Alejandra Bruna María Fernanda García-Bustos Arianna Lourdes Sosa Lochedino María Cristina Salomón Ana Paula Fernandes Juan Pablo Mackern-Oberti Diego Esteban Cargnelutti |
| author_facet | María José Germanó Esteban Sebastián Lozano María Victoria Sanchez Flavia Alejandra Bruna María Fernanda García-Bustos Arianna Lourdes Sosa Lochedino María Cristina Salomón Ana Paula Fernandes Juan Pablo Mackern-Oberti Diego Esteban Cargnelutti |
| author_sort | María José Germanó |
| collection | DOAJ |
| description | BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them. OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)]. METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured. FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection. MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice. |
| first_indexed | 2024-03-12T18:06:38Z |
| format | Article |
| id | doaj.art-acb69b292c804882b90e5ed8aec32594 |
| institution | Directory Open Access Journal |
| issn | 1678-8060 |
| language | English |
| last_indexed | 2024-03-12T18:06:38Z |
| publishDate | 2020-07-01 |
| publisher | Fundação Oswaldo Cruz (FIOCRUZ) |
| record_format | Article |
| series | Memorias do Instituto Oswaldo Cruz |
| spelling | doaj.art-acb69b292c804882b90e5ed8aec325942023-08-02T09:28:10ZengFundação Oswaldo Cruz (FIOCRUZ)Memorias do Instituto Oswaldo Cruz1678-80602020-07-0111510.1590/0074-02760200067Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasisMaría José GermanóEsteban Sebastián LozanoMaría Victoria SanchezFlavia Alejandra BrunaMaría Fernanda García-BustosArianna Lourdes Sosa LochedinoMaría Cristina SalomónAna Paula FernandesJuan Pablo Mackern-ObertiDiego Esteban Cargneluttihttps://orcid.org/0000-0002-1246-7551BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them. OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)]. METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured. FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection. MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762020000100328&tlng=enL. amazonensiswhole-cell vaccinePoly (I:C)leishmaniasis |
| spellingShingle | María José Germanó Esteban Sebastián Lozano María Victoria Sanchez Flavia Alejandra Bruna María Fernanda García-Bustos Arianna Lourdes Sosa Lochedino María Cristina Salomón Ana Paula Fernandes Juan Pablo Mackern-Oberti Diego Esteban Cargnelutti Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis Memorias do Instituto Oswaldo Cruz L. amazonensis whole-cell vaccine Poly (I:C) leishmaniasis |
| title | Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis |
| title_full | Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis |
| title_fullStr | Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis |
| title_full_unstemmed | Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis |
| title_short | Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis |
| title_sort | evaluation of different total leishmania amazonensis antigens for the development of a first generation vaccine formulated with a toll like receptor 3 agonist to prevent cutaneous leishmaniasis |
| topic | L. amazonensis whole-cell vaccine Poly (I:C) leishmaniasis |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762020000100328&tlng=en |
| work_keys_str_mv | AT mariajosegermano evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT estebansebastianlozano evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT mariavictoriasanchez evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT flaviaalejandrabruna evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT mariafernandagarciabustos evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT ariannalourdessosalochedino evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT mariacristinasalomon evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT anapaulafernandes evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT juanpablomackernoberti evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis AT diegoestebancargnelutti evaluationofdifferenttotalleishmaniaamazonensisantigensforthedevelopmentofafirstgenerationvaccineformulatedwithatolllikereceptor3agonisttopreventcutaneousleishmaniasis |